Advertisement
Canada markets open in 1 hour 23 minutes

  • S&P/TSX

    21,516.90
    -94.40 (-0.44%)
     

  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     

  • DOW

    38,834.86
    +56.76 (+0.15%)
     

  • CAD/USD

    0.7294
    -0.0004 (-0.05%)
     

  • CRUDE OIL

    81.71
    +0.14 (+0.17%)
     

  • Bitcoin CAD

    90,713.31
    +1,288.64 (+1.44%)
     

  • CMC Crypto 200

    1,375.52
    -7.14 (-0.52%)
     

  • GOLD FUTURES

    2,353.00
    +6.10 (+0.26%)
     

  • RUSSELL 2000

    2,025.23
    +3.22 (+0.16%)
     

  • 10-Yr Bond

    4.2170
    0.0000 (0.00%)
     

  • NASDAQ futures

    20,025.25
    +106.00 (+0.53%)
     

  • VOLATILITY

    12.59
    +0.11 (+0.88%)
     

  • FTSE

    8,230.31
    +25.20 (+0.31%)
     

  • NIKKEI 225

    38,633.02
    +62.26 (+0.16%)
     

  • CAD/EUR

    0.6803
    +0.0016 (+0.24%)
     

Enfusion (ENFN) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks Equity Research
·2 min read

Enfusion, Inc. (ENFN) reported $48.05 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 17.3%. EPS of $0.06 for the same period compares to $0.03 a year ago.

The reported revenue represents a surprise of +0.80% over the Zacks Consensus Estimate of $47.67 million. With the consensus EPS estimate being $0.04, the EPS surprise was +50.00%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how Enfusion performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Platform subscriptions: $44.69 million versus the four-analyst average estimate of $44.29 million. The reported number represents a year-over-year change of +17.6%.

  • Revenues- Managed services: $3.18 million compared to the $3.22 million average estimate based on four analysts. The reported number represents a change of +15.8% year over year.

  • Revenues- Other: $0.19 million versus the four-analyst average estimate of $0.27 million. The reported number represents a year-over-year change of -18.8%.

View all Key Company Metrics for Enfusion here>>>

Shares of Enfusion have returned +2.2% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Enfusion, Inc. (ENFN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research